Effect of Anti-streptococcus antibody containing tablet on Streptococcus mutans count, causative factor of dental caries.
Phase 4
- Conditions
- Health Condition 1: A488- Other specified bacterial diseases
- Registration Number
- CTRI/2020/02/023667
- Lead Sponsor
- Inzpera Healthsciences Ltd A Subsidiary of Tata Industries Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients having 5 active carious teeth.
Patients not requiring antibiotics.
No systemic illness and pathology.
Exclusion Criteria
Use of systemic Antibiotics in last 30 days.
Use of mouthwash in last 30 days.
Allergic to egg.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does anti-streptococcus IgY in CTRI/2020/02/023667 inhibit Streptococcus mutans adhesion to dental surfaces?
What is the comparative efficacy of anti-streptococcus IgY tablets versus chlorhexidine in reducing S. mutans in caries-active children?
Which salivary biomarkers correlate with response to anti-streptococcus IgY therapy in pediatric dental caries?
What are the safety profiles and adverse event management strategies for anti-streptococcus IgY in Phase IV trials?
How do combination therapies with anti-streptococcus IgY and probiotics impact S. mutans colonization in vivo?